[Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey]

Bull Cancer. 2016 Feb;103(2):154-63. doi: 10.1016/j.bulcan.2015.10.007. Epub 2015 Dec 2.
[Article in French]

Abstract

The prognosis of infracentimetric breast cancers (BC) is heterogeneous. The EURISTIC survey describes how French oncology specialists perceive the prognosis of pT1a,b pN0 BCs. A self-administered questionnaire has been sent to over 2000 French BC specialists. Six hundred and sixty-three physicians responded. Fifty-eight percent do not consider tumor size as a key prognostic criterion. They consider that the cutoff for poor prognosis is 22mm, 10mm and 7mm for hormone receptors (HRs)+, HER2+ and triple-negative (TN) tumors respectively. Eighty-three percent of respondents consider that a HR+ pT1a,b tumor has a good prognosis (21% and 8% for HER2+ and TN respectively). Factors perceived as most detrimental are: HER2 overexpression (29% of respondents); HR- (20%); high grade (20%); TN status (14%); high KI67 (5%); presence of lymphovascular invasion (3%); young age (2%) and high mitotic index (1%). For French specialists, immunohistochemical characteristics, in particular hormone and HER2 status, are strong prognostic factors in BCs below 1cm.

Keywords: Breast cancer; Cancer du sein; PT1a/b pN0; Prognosis; Pronostic.

Publication types

  • English Abstract

MeSH terms

  • Age Factors
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / immunology
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / psychology*
  • Embolism / complications
  • Female
  • France
  • Humans
  • Ki-67 Antigen / metabolism
  • Medical Oncology* / statistics & numerical data
  • Mitotic Index
  • Perception
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Surveys and Questionnaires
  • Triple Negative Breast Neoplasms
  • Tumor Burden*

Substances

  • Ki-67 Antigen
  • Receptors, Estrogen
  • Receptor, ErbB-2